paragraph

<a target="_blank" href="https://mintgenie.livemint.com/stocks/wockhardt-S0003167">Wockhardt Pharma</a> shares have been declining since the start of the year. The stock has dropped 64.37% from its 52-week high of Rs. 592, set on July 2021, and with Thursday's closing price of Rs. 212, the stock is just 4.97% away from its 52-week low.

In just three months, it has fallen 29.46%, while it has lost 50.71% in the last six months. Furthermore, in the last one year, the stock has corrected by almost 60.74%.

On the technical charts, the stock is trading 66.50 per cent below its 200 DMA and 10.50 per cent below its 50-DMA. The Relative Strength Index (RSI) of the stock stands at 37.7.

The Russian-Ukrainian war hit the Indian pharma industry hard as a majority of pharma companies have a strong presence in both countries.

Further, increases in input, logistics, and power costs have damaged the margins of pharma companies in Q4.

Since the beginning of the year, the <a target="_blank" href="https://mintgenie.livemint.com/indices/details/NSI/nifty-pharma-I0016">Nifty Pharma </a>index has dropped approximately 1,499 points, falling to 12,724 from 14,223. The index hit a 52-week low on June 20. Stocks in the index have fallen 20–35% and are trading close to their 52-week lows.

Wockhardt pharma reported a consolidated net loss of ₹311 crore in the fourth quarter ended March 31, 2022, as against a net loss of ₹107 crore in the same period of the previous fiscal.Total revenue during the quarter stood at ₹669 crore as compared to ₹640 crore in the year-ago period. while the total expenses were higher at ₹833 crore as compared to ₹818 crore in the corresponding quarter a year ago.The company said its US business was impacted by price erosion and supply disruptions, with revenue in the quarter at ₹59 crore, down from ₹95 crore in Q4 of FY21.For the fiscal ended March 31, 2022, the consolidated net loss was ₹279 crore. The company had posted a consolidated net profit of ₹688 crore in the previous fiscal.Meanwhile, Rakesh Jhunjhunwala has trimmed his stake in Wockhardt Pharma, according to media reports. In Wockhardt, the big bull has cut his stake to 2.08 per cent in the March 2022 quarter from 2.26 per cent in the December 2021 quarter. However, the number of shares held changed following the rights issue of the company in March 2022.Wockhardt came up with a rights issue of ₹748 crores in March for the issue of up to 3.32 crore rights equity shares at ₹225 per share. The company set a ratio of 3 rights equity shares for every 10 fully paid-up equity shares held by the eligible shareholders on the record date.Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of MintGenie.

Wockhardt Pharma tank 65% this year from its 52-week high hit in July 2021

Wockhardt pharma reported a consolidated net loss of ₹311 crore in the fourth quarter ended March 31, 2022, as against a net loss of ₹107 crore in the same period of the previous fiscal.

Tata Steel Long Products shares decline after it reports losses 

Copper set for worst weekly loss in 28 months

Contrarian views on ACC: Motilal Oswal downgrades, Phillip Capital remains bullish

Should you buy Larsen & Toubro Infotech after Q1? Here's what 4 brokerages say

Adani Ports Rises After Winning Israel Port for $1.2 Billion

Mauritius-based fund house picks up stake in this smallcap multibagger stock

Oil rises on prospects of less aggressive U.S. rate hike

LIC's VNB margin rises to 15.1% in second half of FY22; embedded value flat: Report

India's capital expenditure grew 70% in May; Govt report

Manappuram Finance: Brokerages stay bullish despite a 35% drop in its net profit

In the June quarter, Manappuram Finance reported mixed results. It reported a 32% year-on-year drop in net profit at ₹282.1 crore for the first quarter of the fiscal year, compared to ₹436.5 crore in the previous fiscal.

Income Tax: How to manage your tax issues well

Tax is an important component of your overall financial plan. You should aim to pay the least possible tax without upsetting your investments, which should be designed around your life goals. Read further to know more

SBI Results: Here's why brokerages remain bullish despite Q1 earnings missing estimates

While brokerages were unimpressed by SBI's results on the back of low net interest income (NII) growth and miss in net interest margin (NIM) in the quarter under review but believed the largest public sector lender will report a strong earnings progression right going ahead.

Paytm at near 6-month high as quarterly revenue surges

Paytm, which competes with Google's payment app and Walmart Inc's PhonePe in India's digital payments market, said it is on track to achieve operational profitability by September 2023.

Long-term Investing: Godrej Consumer Products turned ₹1 lakh to ₹75 lakh in 20 years

stocks

In the last 20 years, the stock has jumped from around ₹11 in August 2002 to currently trade around ₹873, rallying as much as 7,474 percent in this period.